Women in clinical studies
Executive Summary
General Accounting Office follow-up report on FDA practices for inclusion of women in clinical drug trials requested by Sens. Harkin (D-Iowa), Mikulski (D-Md.) and Snowe (R-Maine) and Rep. Waxman (D-Calif.) in a May 2 letter. The report will assess changes that have occurred since a 1992 GAO report found inadequate representation of women in clinical trials. FDA issued a proposed rule in 1997 that would require inclusion of women of child-bearing potential in trials
You may also be interested in...
FDA Adverse Event Monitoring "Flaws" Highlighted In GAO Transition Report
Improving the monitoring of drug adverse events is one of FDA's main challenges, a General Accounting Office transition report on HHS indicates.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011